Ritesh Agarwal’s drive has taken Oyo to a multibillion-dollar valuation with a global footprint. His next challenge in the company’s hyper-growth phase will be to iron out persistent issues with hotel partners.
Pharma INR14 crore for a single drug shot: the unfair price of living with a deadly rare disease in India
Nearly 70 million Indians live with some form of rare genetic disease. But for global drug makers, the country isn’t a priority. Unless local firms step up their R&D efforts, the government remedies its lack of policy preparedness, and obscene drug prices are tamed, this population will oscillate between helplessness and despair.
Telcos need to look beyond customer retention and monetise content to grow revenues and profits. But competition and the fear of churn is holding them back in what is still a price-sensitive market. ET Prime examines the various dimensions of the problem to find out the best content-pricing strategy for the telcos.
Disputes The Big 4 come under scrutiny: ICAI slams government stand on multinational accounting firms
The controversy around the presence and structure of global networks in India gets a new twist. ICAI’s Ghia panel says the government-appointed committee report that gave a clean chit to the multinational accounting firms was one-sided, whitewashed blatant violations, and ignored Supreme Court directives.
Electric vehicles Niti Aayog vice chairman Rajiv Kumar’s son joins Ola in policy and corporate affairs wing
Ola has great plans for its electric-vehicles business. The slowing core cab business is making it seek cost-optimisation methods. At the other end, Niti Aayog has been working on a draft policy on EVs for some time now.